CEACAM6 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and bile duct carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM6 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CEACAM6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].